Journals / Bezmiâlem Science / 2015 / Cilt: 3 - Sayı: 2

İdiyopatik Parkinson Hastalığı Motor Semptomlarının Tedavisi

Treatment of Motor Symptoms in Idiopathic Parkinson's Disease

Pages
43–47
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review focuses on treatment strategies for the motor symptoms of idiopathic Parkinson’s disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Idiopathic Parkinson’s disease is one of the most common neurodegenerative disorders.
📊
Key Findings & Data:Idiopathic Parkinson’s disease continues to be a progressive disorder leading to severe disability caused by motor and non-motor symptoms.
💡
Conclusion & Impact:This review focuses on treatment strategies for the motor symptoms of idiopathic Parkinson’s disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Idiopathic Parkinson’s disease is one of the most common neurodegenerative disorders. Idiopathic Parkinson’s disease continues to be a progressive disorder leading to severe disability caused by motor and non-motor symptoms. To date, there have been no disease-modifying or neuroprotective interventions that could stop or slow down disease progression. Treatment of motor symptoms, such as tremor, rigidity, and bradykinesia, is primarily focused on correcting dopamine deficiency. There are some medications that do not directly affect the dopaminergic system. Some invasive interventions are also available. Treatment options should be specified according to age, disease stage, functional status, and concurrent diseases of the patients. Non-motor symptoms, such as sleep disturbances and neuropsychiatric symptoms, should also be properly diagnosed and treated. This review focuses on treatment strategies for the motor symptoms of idiopathic Parkinson’s disease.

Özet

İdiyopatik Parksinson Hastalığı en sık görülen nörodejeneratif hastalıklardan biridir. İdiyopatik Parksinson Hastalığı, motor ve non-motor semptomları ile ciddi özürlülük tablosuna ilerleyen progresif bir hastalıktır. Günümüzde hastalık progresyonunu yavaşlatan ya da durduran nöroprotektif yada hastalık modifiye edici tedavi bulunmamaktadır. Tremor, bradikinezi, rijidite ve postural instabilite gibi motor semptomların tedavisi temelde dopamin eksikliğini düzeltmeye yöneliktir. Direkt olarak dopaminerjik sisteme etki etmeyen bazı ilaçlar mevcuttur. Tedaviye yönelik invazif girişim seçenekleri de bulunmaktadır. Tedavi hastanın yaşı, hastalık evresi, fonksiyonel durumu ve birlikte olan hastalıklara göre şekillendirilmelidir. Ayrıca uyku bozukluğu ve nöropsikiyatrik semptomlar gibi non-motor semptomların da tanınıp tedavi edilmeleri gereklidir. Bu derlemede, Parkinson hastalığının motor semptomlarına yönelik tedavi stratejilerinin gözden geçirilmesi amaçlanmıştır.

🔖

Cite This Article

GÖKÇAL, E., BABACAN, G. Y. (2015). İdiyopatik Parkinson Hastalığı Motor Semptomlarının Tedavisi. Bezmiâlem Science, Cilt: 3 - Sayı: 2, 43–47. https://ajindex.com/articles/352575

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014
  2. [CrossRef] 2. Takahashi H, Wakabayashi K. The cellular pathology of Parkinson’s disease. Neuropathology 2001
  3. [CrossRef] 3. Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson’s disease. CNS Drugs 2013
  4. [CrossRef] 4. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014
  5. [CrossRef] 5. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 2011
  6. [CrossRef] 6. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005
  7. [CrossRef] 7. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009
  8. [CrossRef] 8. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014
  9. [CrossRef] 9. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002
  10. [CrossRef] 10. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005
  11. [CrossRef] 11. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 2007
  12. [CrossRef] 12. Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J, STACCATO study investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy 2014
  13. [CrossRef] 13. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005
  14. [CrossRef] 14. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with an